The Oxford Stem Cell Institute has a close relationship with key centres across the Oxford stem cell landscape.
|Ludwig Cancer Research, a worldwide cancer research organization, engages leading scientists and clinicians in an integrated effort to understand and confront the global challenge of cancer. Research at the Oxford branch encompasses work on cancer stem cells, inflammation and cancer, genetic predisposition, angiogeneisis, epigenetics, hypoxia, medicinal chemistry and protein quality control, with a special emphasis on melanoma and gastrointestinal cancer as model systems.|
|The CRUK Oxford Centre is a network and partnership between Oxford University, Oxford University Hospitals NHS Trust and Cancer Research UK that harnesses Oxford’s world-leading cancer research with the core aim of facilitating collaboration to ensure rapid translation from scientific discovery to treatments for patients.|
|StemBANCC is 5 year academic-industry partnership comprising 35 partners spanning pharmaceutical companies, research institutions and small and medium enterprises (SMEs) that aims to generate and characterise high quality human induced pluripotent stem (iPS) cell lines to study a range of chronic diseases (e.g. diabetes and dementia) and test for drug efficacy and safety.|
|The Oxford Parkinson Disease Centre was created to bring together scientists and clinicians who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, as well as the diagnosis and treatment of Parkinson’s, with an aim to unravel the earliest events in the development of Parkinson’s and identify the changes which occur before the symptoms become apparent.|
|The Oxford Martin School is a community of more than 200 academics based at the University of Oxford working in collaborative teams that cut across disciplines to research complex, global issues that cannot effectively be understood and tackled by any single discipline alone.|
|The Centre for the Advancement of Sustainable Medical Innovation (CASMI), is a partnership between Oxford University and UCL, created to develop new models for medical innovation. The centre aims to address the issues that have led to current failures in the translation of basic bioscience into affordable and widely adopted new treatments.|
|OxStem is a developer of cell reprogramming therapies with the aim of using the Stem Cell and Medicinal Chemistry expertise within Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells to repair damaged tissue in diseases such as Alzheimer’s, diabetes, heart disease and macular degeneration.|